Canadian Respiratory Journal

Canadian Respiratory Journal / 2003 / Article

Case Report | Open Access

Volume 10 |Article ID 612905 | https://doi.org/10.1155/2003/612905

Kevin B Laupland, Doug Helmersen, David A Zygun, Sidney M Viner, "Sildenafil Treatment of Primary Pulmonary Hypertension", Canadian Respiratory Journal, vol. 10, Article ID 612905, 3 pages, 2003. https://doi.org/10.1155/2003/612905

Sildenafil Treatment of Primary Pulmonary Hypertension

Abstract

A 37-year-old woman with primary pulmonary hypertension and worsening symptomatology underwent pulmonary artery (PA) catheterization and vasodilator trials. Oxygen had no effect, but 10 parts/million of nitric oxide reduced mean PA (PAm) pressure by 20%. Prostacyclin infusion at 8 ng/kg/min decreased the PAm pressure by 11%, but further dose increases were limited by systemic hypotension. Sildenafil in doses of 25 mg or higher resulted in an average decrease of 14% in PAm pressure. Sildenafil is a potentially useful treatment option for patients with primary pulmonary hypertension, and further investigation is warranted.

Copyright © 2003 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views159
Downloads247
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.